SAN DIEGO–(BUSINESS WIRE)–Progenity,
Inc., a privately held biotechnology company developing precision
medicine solutions across genomic/epigenomic, proteomic, and microbiomic
diagnostic and therapeutic platforms, announced today that the company
will be participating in the Raymond James Life Sciences and MedTech
Conference in New York, June 18 and 19.
Chief Executive Officer Harry Stylli, Ph.D., will present a corporate
overview on Wednesday, June 19, from 10:55 AM to 11:25 AM EDT. Dr.
Stylli and Eric d’Esparbes, Chief Financial Officer, will also
participate in one-on-one meetings with investors.
About Progenity
Progenity, Inc., is a privately held biotechnology company with the
mission of transforming healthcare to be more precise and personal. The
company is translating innovation into precision medicine through
diagnostic and therapeutic development platforms based on
genomics/epigenomics, proteomics, and microbiomics. These platforms feed
an R&D pipeline of innovative products designed to improve patient
outcomes in prenatal and perinatal healthcare settings, oncology, and
gastroenterology. Progenity’s ultimate vision is to make precision
medicine a reality by both diagnosing disease at its source and treating
it with targeted therapies developed by the company. Progenity is
headquartered in San Diego, California. For more information on how
Progenity is helping clinicians and patients prepare for life, please
visit www.progenity.com.
Contacts
Nicole Goelz
CG Life
ngoelz@cglife.com
(858)
457-2436
Investor Contact
IR@progenity.com